Aadi Bioscience (AADI) Stock Forecast, Price Target & Predictions
AADI Stock Forecast
Aadi Bioscience stock forecast is as follows: an average price target of $1.63 (represents a -9.44% downside from AADI’s last price of $1.80) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
AADI Price Target
The average price target for Aadi Bioscience (AADI) is $1.63 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $1.75 to $1.50. This represents a potential -9.44% downside from AADI's last price of $1.80.
AADI Analyst Ratings
According to 4 Wall Street analysts, Aadi Bioscience's rating consensus is 'Hold'. The analyst rating breakdown for AADI stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 4 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Aadi Bioscience Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 27, 2024 | Joseph Catanzaro | Piper Sandler | $1.75 | $1.75 | - | -2.78% |
| Aug 21, 2024 | Roger Song | Jefferies | $1.50 | $1.55 | -3.23% | -16.67% |
The latest Aadi Bioscience stock forecast, released on Aug 27, 2024 by Joseph Catanzaro from Piper Sandler, set a price target of $1.75, which represents a 0.00% decrease from the stock price at the time of the forecast ($1.75), and a -2.78% decrease from AADI last price ($1.80).
Aadi Bioscience Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 2 |
| Avg Price Target | $1.63 | $1.63 | $1.63 |
| Last Closing Price | $1.80 | $1.80 | $1.80 |
| Upside/Downside | -9.44% | -9.44% | -9.44% |
In the current month, the average price target of Aadi Bioscience stock is $1.63, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a -9.44% decrease as opposed to Aadi Bioscience's last price of $1.80. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Piper Sandler | - | Neutral | Downgrade |
| Aug 21, 2024 | Jefferies | Buy | Hold | Downgrade |
| Aug 21, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Aug 21, 2024 | Cowen & Co. | - | Hold | Downgrade |
| May 09, 2024 | Jefferies | Buy | Buy | Hold |
Aadi Bioscience's last stock rating was published by Piper Sandler on Aug 27, 2024. The company Downgrade its AADI rating from "null" to "Neutral".
Aadi Bioscience Financial Forecast
Aadi Bioscience Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Dec 20 | Jun 20 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $5.96M | $6.20M | $5.87M | $5.23M | $4.25M | - | $2.31M | $1.00M | - | $14.00M | $15.00M | $18.82M | $1.33M |
| Avg Forecast | $7.22M | $7.10M | $6.95M | $6.85M | $6.87M | $6.58M | $6.19M | $6.47M | $6.29M | $6.62M | $6.20M | $5.48M | $4.82M | $3.74M | $2.75M | $375.75K | $45.00K | $78.75K | $2.00M | $15.00M | $19.49M | $1.33M |
| High Forecast | $7.60M | $7.48M | $7.32M | $7.21M | $7.24M | $6.93M | $6.52M | $6.81M | $6.42M | $6.97M | $6.53M | $5.77M | $5.08M | $3.94M | $2.75M | $385.24K | $46.14K | $80.74K | $2.05M | $15.38M | $23.39M | $1.60M |
| Low Forecast | $6.86M | $6.74M | $6.60M | $6.51M | $6.53M | $6.27M | $5.88M | $6.15M | $6.14M | $6.29M | $5.89M | $5.21M | $4.58M | $3.55M | $2.75M | $361.23K | $43.26K | $75.71K | $1.92M | $14.42M | $15.60M | $1.07M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 14 | 8 | 16 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.90% | 1.00% | 1.07% | 1.08% | 1.14% | - | 6.14% | 22.22% | - | 7.00% | 1.00% | 0.97% | 1.00% |
Aadi Bioscience's average Quarter revenue forecast for Dec 23 based on 4 analysts is $6.29M, with a low forecast of $6.14M, and a high forecast of $6.42M. AADI's average Quarter revenue forecast represents a 5.60% increase compared to the company's last Quarter revenue of $5.96M (Sep 23).
Aadi Bioscience EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Dec 20 | Jun 20 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 14 | 8 | 16 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-17.85M | $-19.55M | $-15.16M | $-13.86M | $-14.40M | - | $-13.72M | $-15.86M | $-86.93M | $-4.70M | $9.29M | $11.55M | $-5.98M |
| Avg Forecast | $-6.05M | $-5.95M | $-5.82M | $-5.74M | $-5.76M | $-5.51M | $-5.19M | $-5.42M | $-5.27M | $-5.55M | $-5.19M | $-4.59M | $-4.04M | $-3.13M | $-2.31M | $-14.69M | $-37.70K | $-65.98K | $-1.68M | $-12.57M | $11.95M | $-5.98M |
| High Forecast | $-5.75M | $-5.65M | $-5.53M | $-5.45M | $-5.47M | $-5.26M | $-4.93M | $-5.15M | $-5.14M | $-5.27M | $-4.93M | $-4.36M | $-3.84M | $-2.97M | $-2.31M | $-11.75M | $-36.25K | $-63.43K | $-1.61M | $-12.08M | $14.34M | $-4.78M |
| Low Forecast | $-6.37M | $-6.27M | $-6.13M | $-6.04M | $-6.07M | $-5.80M | $-5.46M | $-5.71M | $-5.38M | $-5.84M | $-5.47M | $-4.84M | $-4.25M | $-3.30M | $-2.31M | $-17.63M | $-38.66K | $-67.65K | $-1.72M | $-12.89M | $9.56M | $-7.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.22% | 3.76% | 3.30% | 3.43% | 4.60% | - | 0.93% | 420.67% | 1317.41% | 2.81% | -0.74% | 0.97% | 1.00% |
14 analysts predict AADI's average Quarter EBITDA for Dec 20 to be $-1.68M, with a high of $-1.61M and a low of $-1.72M. This is -118.04% lower than Aadi Bioscience's previous annual EBITDA (Jun 20) of $9.29M.
Aadi Bioscience Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Dec 20 | Jun 20 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 14 | 8 | 16 | 18 |
| Net Income | - | - | - | - | - | - | - | - | - | $-16.30M | $-17.97M | $-13.68M | $-13.91M | $-13.32M | - | $-13.90M | $-16.05M | $-87.09M | $-4.72M | $9.28M | $11.54M | $-5.99M |
| Avg Forecast | $-10.20M | $-9.05M | $-8.71M | $-8.64M | $-9.13M | $-12.21M | $-18.64M | $-16.85M | $-17.50M | $-19.56M | $-16.80M | $-15.77M | $-18.03M | $-20.04M | $-20.24M | $-14.83M | $-22.22M | $-15.57M | $-53.94M | $109.21M | $11.94M | $-5.99M |
| High Forecast | $-9.53M | $-8.46M | $-8.14M | $-8.08M | $-8.53M | $-7.70M | $-17.42M | $-15.76M | $-16.20M | $-18.28M | $-15.70M | $-14.75M | $-16.85M | $-18.73M | $-20.24M | $-11.87M | $-21.10M | $-14.79M | $-51.23M | $112.80M | $14.32M | $-4.79M |
| Low Forecast | $-10.90M | $-9.67M | $-9.31M | $-9.24M | $-9.76M | $-15.92M | $-19.93M | $-18.02M | $-19.07M | $-20.91M | $-17.96M | $-16.86M | $-19.28M | $-21.43M | $-20.24M | $-17.80M | $-22.95M | $-16.08M | $-55.71M | $103.73M | $9.55M | $-7.19M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.83% | 1.07% | 0.87% | 0.77% | 0.66% | - | 0.94% | 0.72% | 5.59% | 0.09% | 0.08% | 0.97% | 1.00% |
Aadi Bioscience's average Quarter net income forecast for Dec 20 is $-53.94M, with a range of $-55.71M to $-51.23M. AADI's average Quarter net income forecast represents a -681.48% decrease compared to the company's last Quarter net income of $9.28M (Jun 20).
Aadi Bioscience SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Dec 20 | Jun 20 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 14 | 8 | 16 | 18 |
| SG&A | - | - | - | - | - | - | - | - | - | $11.22M | $11.78M | $11.21M | $11.11M | $9.91M | - | $9.15M | $9.72M | $7.40M | $2.41M | $2.20M | $3.28M | $3.14M |
| Avg Forecast | $52.07M | $51.20M | $50.12M | $49.40M | $49.57M | $47.42M | $44.64M | $46.66M | $45.38M | $47.74M | $44.69M | $39.52M | $34.76M | $26.95M | $19.85M | $2.71M | $324.50K | $567.88K | $14.42M | $108.17M | $3.39M | $9.61M |
| High Forecast | $54.83M | $53.92M | $52.78M | $52.02M | $52.21M | $49.95M | $47.01M | $49.14M | $46.29M | $50.28M | $47.06M | $41.62M | $36.61M | $28.38M | $19.85M | $2.78M | $332.69K | $582.22K | $14.79M | $110.90M | $4.07M | $11.54M |
| Low Forecast | $49.45M | $48.63M | $47.60M | $46.92M | $47.08M | $45.25M | $42.40M | $44.32M | $44.25M | $45.34M | $42.45M | $37.54M | $33.01M | $25.59M | $19.85M | $2.60M | $311.96K | $545.93K | $13.87M | $103.99M | $2.71M | $7.69M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.24% | 0.26% | 0.28% | 0.32% | 0.37% | - | 3.38% | 29.95% | 13.03% | 0.17% | 0.02% | 0.97% | 0.33% |
Aadi Bioscience's average Quarter SG&A projection for Dec 23 is $45.38M, based on 4 Wall Street analysts, with a range of $44.25M to $46.29M. The forecast indicates a 304.39% rise compared to AADI last annual SG&A of $11.22M (Sep 23).
Aadi Bioscience EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Dec 20 | Jun 20 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 14 | 8 | 16 | 18 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.51 | $-0.52 | $-0.63 | - | $-0.66 | $-0.77 | $-9.17 | $-1.50 | $3.40 | $4.22 | $-3.29 |
| Avg Forecast | $-0.38 | $-0.34 | $-0.32 | $-0.32 | $-0.34 | $-0.45 | $-0.69 | $-0.62 | $-0.65 | $-0.72 | $-0.62 | $-0.58 | $-0.67 | $-0.74 | $-0.75 | $-0.70 | $-0.82 | $-0.58 | $-2.00 | $4.05 | $0.30 | $-0.22 |
| High Forecast | $-0.35 | $-0.31 | $-0.30 | $-0.30 | $-0.32 | $-0.28 | $-0.65 | $-0.58 | $-0.60 | $-0.68 | $-0.58 | $-0.55 | $-0.62 | $-0.69 | $-0.75 | $-0.67 | $-0.78 | $-0.55 | $-1.90 | $4.18 | $0.36 | $-0.18 |
| Low Forecast | $-0.40 | $-0.36 | $-0.34 | $-0.34 | $-0.36 | $-0.59 | $-0.74 | $-0.67 | $-0.71 | $-0.77 | $-0.67 | $-0.62 | $-0.71 | $-0.79 | $-0.75 | $-0.73 | $-0.85 | $-0.60 | $-2.07 | $3.85 | $0.24 | $-0.26 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.87% | 0.78% | 0.85% | - | 0.94% | 0.93% | 15.88% | 0.75% | 0.84% | 14.07% | 14.94% |
According to 14 Wall Street analysts, Aadi Bioscience's projected average Quarter EPS for Dec 20 is $-2.00, with a low estimate of $-2.07 and a high estimate of $-1.90. This represents a -158.83% decrease compared to AADI previous annual EPS of $3.40 (Jun 20).
Aadi Bioscience Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| RARE | Ultragenyx Pharmaceutical | $58.74 | $108.14 | 84.10% | Buy |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
| KURA | Kura Oncology | $20.88 | $28.67 | 37.31% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| AADI | Aadi Bioscience | $1.80 | $1.63 | -9.44% | Hold |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
AADI Forecast FAQ
Is Aadi Bioscience a good buy?
No, according to 4 Wall Street analysts, Aadi Bioscience (AADI) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of AADI's total ratings.
What is AADI's price target?
Aadi Bioscience (AADI) average price target is $1.63 with a range of $1.5 to $1.75, implying a -9.44% from its last price of $1.8. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Aadi Bioscience stock go up soon?
According to Wall Street analysts' prediction for AADI stock, the company can go down by -9.44% (from the last price of $1.8 to the average price target of $1.63), down by -2.78% based on the highest stock price target, and down by -16.67% based on the lowest stock price target.
Can Aadi Bioscience stock reach $3?
AADI's average twelve months analyst stock price target of $1.63 does not support the claim that Aadi Bioscience can reach $3 in the near future.
What is Aadi Bioscience's current price target trend?
2 Wall Street analysts forecast a $1.63 price target for Aadi Bioscience (AADI) this month, down -9.44% from its last price of $1.8. Compared to the last 3 and 12 months, the average price target decreased by -9.44% and decreased by -9.44%, respectively.
What are Aadi Bioscience's analysts' financial forecasts?
Aadi Bioscience's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $26.11M (high $27.5M, low $24.83M), average EBITDA is $-21.877M (high $-20.804M, low $-23.042M), average net income is $-56.829M (high $-49.408M, low $-63.63M), average SG&A $188.28M (high $198.31M, low $179.05M), and average EPS is $-2.104 (high $-1.829, low $-2.356). AADI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $28.12M (high $29.62M, low $26.71M), average EBITDA is $-23.561M (high $-22.38M, low $-24.815M), average net income is $-36.599M (high $-34.213M, low $-39.129M), average SG&A $202.78M (high $213.56M, low $192.61M), and average EPS is $-1.355 (high $-1.267, low $-1.449).
Did the AADI's actual financial results beat the analysts' financial forecasts?
Based on Aadi Bioscience's last annual report (Dec 2023), the company's revenue was $24.35M, which missed the average analysts forecast of $24.59M by -0.96%. Apple's EBITDA was $-71.933M, beating the average prediction of $-20.604M by 249.12%. The company's net income was $-65.765M, missing the average estimation of $-69.632M by -5.55%. Apple's SG&A was $44.55M, missing the average forecast of $177.32M by -74.88%. Lastly, the company's EPS was $-0.0024, missing the average prediction of $-2.578 by -99.91%. In terms of the last quarterly report (Sep 2023), Aadi Bioscience's revenue was $5.96M, missing the average analysts' forecast of $6.62M by -9.98%. The company's EBITDA was $-17.849M, beating the average prediction of $-5.547M by 221.79%. Aadi Bioscience's net income was $-16.302M, missing the average estimation of $-19.555M by -16.64%. The company's SG&A was $11.22M, missing the average forecast of $47.74M by -76.49%. Lastly, the company's EPS was $-0.0006, missing the average prediction of $-0.724 by -99.92%